Welcome to our dedicated page for Precigen news (Ticker: PGEN), a resource for investors and traders seeking the latest updates and insights on Precigen stock.
Precigen, Inc. reports developments as a commercial-stage biopharmaceutical company advancing precision medicines for difficult-to-treat diseases. Its news centers on PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved therapy for adults with recurrent respiratory papillomatosis, including commercialization, access, reimbursement, medical-publication updates, and adoption by treating physicians.
Company updates also cover financial results, business presentations, and pipeline activity across immuno-oncology, autoimmune disorders, and infectious diseases. Precigen’s recurring technology references include the AdenoVerse immunotherapy platform, UltraCAR-T programs, and related manufacturing capabilities used to support its precision-medicine portfolio.
On January 12, 2022, Precigen (PGEN) showcased key updates at the 40th Annual J.P. Morgan Healthcare Conference. Highlights included the completion of enrollment in several Phase 1/1b clinical trials for investigational therapies targeting Acute Myeloid Leukemia (AML), ovarian cancer, and recurrent respiratory papillomatosis (RRP). Notably, the firm reported positive interim data from multiple studies, with plans to initiate multicenter expansions and incorporate repeat dosing regimens. Additionally, Precigen aims for rapid regulatory strategies for its therapies addressing significant unmet medical needs in 2022.
Precigen, a biopharmaceutical company listed on Nasdaq under the ticker PGEN, announced that CEO Helen Sabzevari will provide a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 3:45 PM ET. Additionally, she will join a panel discussion on January 11, 2022, at 12:00 PM ET, discussing the cell and gene therapy landscape. Live webcasts of both events can be accessed on Precigen's website.
Precigen presented promising interim results for its PRGN-3006 UltraCAR-T therapy targeting relapsed or refractory acute myeloid leukemia (AML) at the 63rd ASH Annual Meeting. The Phase 1/1b study included 15 patients, showing an overall response rate (ORR) of 50% in the lymphodepletion cohort. Notably, the therapy was well-tolerated, with no dose-limiting toxicities or neurotoxicity. The company anticipates progressing to a multicenter expansion phase to evaluate repeated dosing. These results highlight the potential of UltraCAR-T in transforming AML treatment pathways.
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company, will have its President and CEO, Helen Sabzevari, participate in the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 10:40 AM ET. This event can be accessed via the Precigen website. The company is focused on gene and cell therapies aimed at treating urgent diseases, including in the areas of immuno-oncology and autoimmune disorders. More information can be found on their website.
Precigen (Nasdaq: PGEN) announced significant clinical progress during its 2021 R&D Day, showcasing advancements in its UltraCAR-T and AdenoVerse therapy platforms. Highlights include favorable safety and efficacy data from PRGN-3005, PRGN-3006, PRGN-2009, and PRGN-2012 therapies. Notably, PRGN-3006 demonstrated a 50% overall response rate in relapsed or refractory AML patients. Additionally, PRGN-2009 showed promising immune responses in HPV-associated cancers. Future plans include pursuing registrational trials pending dose confirmation. Overall, the event emphasized Precigen's commitment to advancing innovative therapies for complex diseases.
Precigen (Nasdaq: PGEN) will host a virtual event on November 4, 2021, at 11:00 AM ET to discuss updates on its clinical pipeline. The event will present data on several advanced programs, including PRGN-3005 and PRGN-3006 UltraCAR-T, as well as PRGN-2009 and PRGN-2012 AdenoVerse Immunotherapies. Executives and lead investigators from notable institutions will participate. Details for registration and access to the live webcast are available on Precigen's investor relations website.
Precigen has announced that the FDA has cleared its IND application to launch a Phase 1/1b clinical trial for PRGN-3007, targeting advanced ROR1+ hematological and solid tumors. This first-in-class therapy, leveraging Precigen's UltraCAR-T® platform, aims to improve outcomes in patients with cancers like CLL and TNBC by incorporating PD-1 blockade. The trial will assess safety and efficacy in two arms: one for hematological tumors and another for solid tumors. This innovative therapy is expected to mitigate systemic toxicity and reduce treatment costs.
Precigen, Inc. (Nasdaq: PGEN) announced the appointment of Harry Thomasian Jr. as its new chief financial officer (CFO), effective October 18, 2021. With over 35 years of global finance experience, Thomasian will oversee corporate financial strategy, business development, and financing initiatives. Prior to joining Precigen, he held leadership roles at EY, focusing on the life sciences sector. CEO Helen Sabzevari emphasized Thomasian's financial acumen and experience as vital for guiding the company's growth and fiscal strength.
Precigen ActoBio announced encouraging interim data from its Phase 1b/2a clinical study of AG019 ActoBiotics for recent-onset type 1 diabetes. Presenting at the EASD 57th Annual Meeting, results demonstrated AG019’s safety and efficacy, with 100% of adult patients achieving glycated hemoglobin below 7% after monotherapy. The study met primary endpoints; no serious adverse events occurred. AG019 also stabilized C-peptide levels, indicating preserved insulin production. Future investigations will explore AG019's potential as a standalone therapy for type 1 diabetes.
Precigen, Inc. (Nasdaq: PGEN) announced that Dr. Helen Sabzevari will participate in two key conferences. She will engage in a virtual fireside chat at the Wells Fargo Virtual Healthcare Conference on September 9, 2021, at 8:40 AM ET. Additionally, she will present at the H.C. Wainwright 23rd Annual Global Investment Conference, with the webcast available on-demand starting September 13, 2021, at 7:00 AM ET. Webcast access is available via Precigen's website.